TABLE 2.
Mean (S.D.) levetiracetam brain concentrations and corresponding mean brain-to-plasma ratios in naïve and LFPI rats with continuous 7-day LEV subcutaneous treatment (n = 3 per group per time point)
| Naïve | LFPI | |||||||
|---|---|---|---|---|---|---|---|---|
| Time (h) | RCCX | LCCX | RCCX | LCCX | ||||
| Conc (μg/ml) | Brain: Plasma | Conc (μg/ml) | Brain: Plasma | Conc (μg/ml) | Brain: Plasma | Conc (μg/ml) | Brain: Plasma | |
| 1 | 161 (20.1) | 0.54 | 131 (13.2) | 0.63 | 109 (26.4) | 0.72 | 138 (49.9) | 0.90 |
| 120 | 110 (16.7) | 0.76 | 106 (11.3) | 0.79 | 109 (15.4) | 1.06 | 124 (13.0) | 1.2 |
| 172 | 12.0 (1.48) | 0.72 | 9.91 (3.93)b | 0.95 | 9.55 (5.51)a | 0.85 | 18.5 (6.61)a,b | 1.4 |
aStatistically significant difference between RCCX and LCCX of LFPI (P = 0.02, Student’s t test).
bStatistically significant difference in LCCX concentrations between naïve and LFPI rats (P = 0.02, Student’s t test).